Grant: Discovery Grants Program - Individual
McGill University
$21,000.00
Modeling imaging data
FY 2017-18
Summary
Positron Emission Tomography (PET) associated to radiopharmaceuticals constitutes an ideal non-invasive imaging method for quantification of brain neurodegenerative processes. AIMS: The aims of the present research is to develop novel technologies for in vivo quantification brain molecular processes using PET imaging agents as well as magnetic resonance imaging (MRI) techniques. These goals entail two major milestones. Firstly, proof of concept studies conducted in vitro preparations as well as in animal models. Subsequently further studies will validate these novel methodologies in living animals for KAL-ABP, MNI-387, [11C]PBR28, [18F]MK6240, [18F]FEOBV to measure microglia activation, protein aggregates and cholinergic transport. DELIVERABLES: This research program will (1) characterize the binding of novel radiopharmaceuticals in vitro (2) provide proof of concept data conducted in in animal models; (3) Furthermore, the present research program incorporates the training of high-qualified personal to conduct, analyze and interpret and integrate imaging to behavior outcome measures. To this end, our Canadian Foundation for Innovation (CFI) funded imaging laboratory provides a unique environment for trainees and students to conduct of in vitro imaging. Furthermore our laboratory infrastructure is integrated to in vivo data acquisition core facilities such as the Douglas Imaging Centre (MRI acquisition), Douglas neurophenotype unit (animal behavioral measures) and the Montreal neurological Institute Brain Imaging Centre (PET acquisition). FORMATION OF HUMAN RESOURCES: the project will provide a unique training environment for junior scientists, engineers and neuroinformatics professionals interested in developing in vivo methodologies for monitoring brain function. IMPACT: Novel technologies capable to capture non invasively aging-related processes in normal individuals constitute one of the major challenges in biomedicine, which will ultimately expands the comprehension of mechanisms underlying healthy aging.
Program
Discovery Grants Program - Individual
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
RGPIN-2017-06905
Name nom
RosaNeto, Pedro
Department département
Neurology and Neurosurgery - Neurology and Neurosurgery
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
21000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1505
Committee name en
Physics
Committee name fr
Physique
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
5305
Research subject group en
Molecular biology
Research subject group fr
Biologie moléculaire
Research subject en
Protein manipulation and expression
Research subject fr
Expression et recombinaison protéiques
Partie
1
Nb partie
1
Application title
Modeling imaging data
Keyword
NSERC
Application summary
Positron Emission Tomography (PET) associated to radiopharmaceuticals constitutes an ideal non-invasive imaging method for quantification of brain neurodegenerative processes. AIMS: The aims of the present research is to develop novel technologies for in vivo quantification brain molecular processes using PET imaging agents as well as magnetic resonance imaging (MRI) techniques. These goals entail two major milestones. Firstly, proof of concept studies conducted in vitro preparations as well as in animal models. Subsequently further studies will validate these novel methodologies in living animals for KAL-ABP, MNI-387, [11C]PBR28, [18F]MK6240, [18F]FEOBV to measure microglia activation, protein aggregates and cholinergic transport. DELIVERABLES: This research program will (1) characterize the binding of novel radiopharmaceuticals in vitro (2) provide proof of concept data conducted in in animal models; (3) Furthermore, the present research program incorporates the training of high-qualified personal to conduct, analyze and interpret and integrate imaging to behavior outcome measures. To this end, our Canadian Foundation for Innovation (CFI) funded imaging laboratory provides a unique environment for trainees and students to conduct of in vitro imaging. Furthermore our laboratory infrastructure is integrated to in vivo data acquisition core facilities such as the Douglas Imaging Centre (MRI acquisition), Douglas neurophenotype unit (animal behavioral measures) and the Montreal neurological Institute Brain Imaging Centre (PET acquisition). FORMATION OF HUMAN RESOURCES: the project will provide a unique training environment for junior scientists, engineers and neuroinformatics professionals interested in developing in vivo methodologies for monitoring brain function. IMPACT: Novel technologies capable to capture non invasively aging-related processes in normal individuals constitute one of the major challenges in biomedicine, which will ultimately expands the comprehension of mechanisms underlying healthy aging.